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Canine leishmaniosis (CanL) prevention in the Mediterranean basin is considered
essential to stop human zoonotic visceral leishmaniasis. In this context, vaccination of
dogs is expected to have a significant impact in disease control. CaniLeish® (Virbac
Animal Health) is one of a few CanL vaccines that are at this moment licensed in
Europe. This vaccine contains purified excreted-secreted proteins of Leishmania having
several antigens/immunogens with potential to influence serological response. Therefore,
it is important to know if CaniLeish vaccination increased the diagnostic challenges
associated with conventional serology, limiting the value of some antigens. To address
this 20 dogs from a cohort of 35 healthy dogs that were vaccinated, maintained indoor
for 1 month and then returned to their natural domiciles for 2 years. After this period, they
were re-called to evaluate their clinical/parasitological condition and assess the evolution
of seroreactivity against different antigens: soluble promastigote Leishmania antigens
(SPLA), recombinant protein Leishmania infantum cytosolic peroxiredoxin, recombinant
protein K39 (rK39), recombinant protein K28 and recombinant kinesin degenerated
derived repeat using ELISA. Two years after vaccination all vaccinated non-infected
animals were seropositive for SPLA. For the other antigens the serological profile was
indistinguishable from non-infected animals. Moreover, vaccinated animals presented a
characteristic relative serological profile, with higher normalized serological response to
SPLA than rK39. This fact enabled to distinguish with sensitivity 92.3% and specificity
95.4%, vaccinated non-infected dogs from infected and non-infected dogs. Ultimately,
relative serological profile enabled the detection of healthy vaccinated animals enabling
more accurate serological surveys.
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INTRODUCTION
Canine leishmaniosis (CanL) is a vector-borne zoonotic disease,
caused by protozoan parasites of the genus Leishmania, present
in four continents impacting veterinary and public health
(1–3). Moreover, the prevalence of human zoonotic visceral
leishmaniasis (ZVL) and CanL, in endemic areas, are associated
(4–6). Although early diagnosis, treatment, vector, and reservoir
control are part of surveillance programs to control CanL
(3, 7, 8), vaccination is considered an important tool to
prevent the human and canine disease (9–11). Currently, in
Europe, there are two available canine vaccines: CaniLeish R©
and LetiFend R© (8, 12). The CaniLeish vaccine contains
excreted/secreted antigens purified from the culture supernatant
of Leishmania infantum promastigotes. The proteomic studies
on excreted/secreted antigens confirm the existence of several
proteins that are not exclusively secreted, being also present
in parasite preparations (13, 14). Therefore, as CaniLeish
induces Th1 cell-mediated response and production of IgG1
and IgG2 antibodies, seroreactivity due to natural infection or
due to immunoprophylaxis is difficult to distinguish as cross-
reactivity to several Leishmania antigens can occur (8, 15).
Therefore, considering that CaniLeish is now available for over
7 years and vaccine-induced anti-Leishmania antibodies can
be detectable for months after administration, it is important
to evaluate if vaccine-induced seroconversion might represent
a problem in surveillance and control programs (15). To
address this possibility, serum of CaniLeish vaccinated dogs
from a previous study (8), that involved the vaccination of
20 dogs from a cohort of 35 naive dogs and a subsequent
2 years follow up, was used to evaluate the evolution
of seroreactivity to diagnosis relevant antigens like SPLA
(soluble promastigote Leishmania antigens), rK39 and other
molecules of high serological value like the kinesins constructs
rK28 (16), recombinant kinesin degenerated derived repeat
(rKDDR) (17) or recombinant protein Leishmania infantum
cytosolic peroxiredoxin (LicTXNPx) (18) using enzyme-linked
immunosorbent assay (ELISA).With the exception of LicTXNPx,
a peroxiredoxin associated to the protection of the parasites
from oxidative stress (19) all the recombinant proteins used are
synthetic peptides containing or enriched in immunodominant
epitopes. The rK39 is a repetitive immunodominant epitope
from a kinesin-related protein conserved in viscerotropic
Leishmania (20). The kDDR is a 39 amino acid repetitive
sequence originated from an originated from an in-silico epitope
prediction analysis (17). The rK28 is a synthetic construct created
by fusing multiple tandem repeat sequences of Leishmania




The study from which the serological samples originated
involved cohort of 35 healthy dogs was studied for 2 years (8).
Previously, parasitological (PCR from BoneMarrow and culture)
and serological tests Indirect Fluorescence Antibody Test (IFAT)
were performed to confirm the absence of Leishmania infection.
Twenty dogs were vaccinated (V) with CaniLeish R© (standard
formulation) and 15 non-vaccinated animals were included as
controls (NV). Primo-vaccination program was done in 3 doses
with 21 days of interval each. After the last dose dogs were
housed in kennels with insecticide nets for 1 more month.
After this period the animals returned to their domiciles. A
booster vaccination was performed 1 year after the third dose
of primo-vaccination.
Sampling
Samples were collected at two-time points as described in
the original study (8): M1 (1 month after the administration
of the last dose of primo-vaccination, at the end of their
period in the kennel) and M25 (25 months after the last dose
of primo-vaccination). IFAT (Indirect Fluorescence Antibody
Test), PCR and culture assays were performed in the two-
time points (8). Clinical surveillance was also done to
evaluate clinical manifestations compatible with CanL. At the
end of the study, the cohort was sub-divided in 4 groups
concerning PCR and clinical evaluation: C- (non-vaccinated
non-infected animals), C+ (non-vaccinated infected animals),
V- (vaccinated non-infected animals), and V+ (vaccinated
infected animals).
Antigens
For SPLA, Leishmania promastigotes were cultivated as
previously described (22). Parasites with 5 days of culture were
then washed 3 times with phosphate-buffered saline (PBS) pH
7.4 and centrifuged at 3,500 × g, 10min, at 4◦C. The pellet
was then suspended at a concentration of 108 parasites/ml in
PBS containing 1mM phenylmethylsulfonyl fluoride protease
inhibitor and submitted to 10 freeze-thaw cycles for rupture of
the parasites. This suspension was centrifuged at 13,000 × g,
30min, at 4◦C and the supernatant was recovered, quantified by
DC (detergent compatible)TM Protein Assay (BioRad, Germany),
and stored at −80◦C in single-use aliquots. The recombinant
protein LicTXNPx was purified by affinity chromatography on
a Ni-NTA column (Qiagen) as described in previous reports
(23) and obtained as a recombinant protein containing six
histidine residues at its N-terminal. The rLicTXNPx was
quantified and stored at −80◦C in single aliquots. The rK39
and rK28 lyophilized antigens, obtained from Dr. Steven Reed,
from Infectious Disease Research Institute (Seattle, USA)
were suspended in deionized and 0.22µm membrane-filtered
H2O, quantified and stored at −80
◦C in single use-aliquots.
The recombinant protein rKDDR, provided by Dr. Ricardo
Fujiwara, from Universidade Federal de Minas Gerais (Belo
Horizonte, Brasil), was quantified and stored at −80◦C in
single aliquots.
Evaluation of Seroreactivity
The serological reactivity in the canine samples was evaluated by
ELISA using each of the 5 different antigens: SPLA, LicTXNPx,
rK39, K28, and rKDDR. Ninety-six-well flat-bottomedmicrotiter
plates (Greiner Bio-One) were coated with 50 µl of 0.1M
carbonate buffer, pH = 9.6, with 10µg/ml of SPLA, 3µg/ml of
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LicTXNPx, 1µg/ml of rK39, 4µg/ml of rK28, and 3µg/ml of
rKDDR. Plates were incubated overnight at 4◦C and blocked
with 200 µl of PBS-low-fat-milk 3% at 37◦C for 1 h. Next,
plates were washed with PBS-Tween 0.05% (PBS-T), and the
sera, positive and negative controls diluted 1:1,500 in PBS-T-
low-fat-milk 1%, were dispensed in triplicate (100 µl/well) and
incubated at 37◦C for 30min. Wells that have the antigen, that
are blocked and only incubated with the secondary antibody
are the blank situation that works as a negative control. As
an internal positive control we used a mixture of sera from
several highly seropositive positive CanL dogs. This pool was
made aliquoted and used for the duration of the study. When
a batch is finishing a new blend of pooled CanL sera is done
and then compared to the old batch to confirm the new internal
positive control. Consequently, the OD obtained for each antigen
is characteristic of the positive control and in conjunction with
the negative control above mentioned enables the required
quality control for each assay, assuring greater reproducibility.
After a washing step, 100 µl/well of secondary antibody—
anti-dog IgG conjugated to horseradish peroxidase (Sigma)—
diluted 1:1176.5, was added and the plates were incubated
at 37◦C for 30min. Plates were washed and incubated with
0.5 mg/ml of o-phenylenediamine dihydrochloride (Sigma) for
10min in the dark. The reaction was stopped with 50 µl/well
of HCl 3M. Absorbance was read at 492 nm in an automatic
reader (Synergy 2, BioTek Instruments, Inc., Vermont). All
samples and antigens were assayed in triplicate in at least two
independent assays.
Statistical Analysis
Receiver operating characteristic (ROC) curves were generated
using sera from two distinct groups of animals: 29 dogs with
confirmed CanL living in geographical regions of Portugal where
CanL is endemic and 121 non-infected dogs originated from a
non-endemic region from Portugal. A 95% confidence interval
(95% CI) for the area under the ROC curve was considered.
Cut-off values were inferred through these curves for each
antigen (by choosing the best compromise between sensitivity
and specificity associated with the ROC curve). The optical
densities (OD) of each sample were normalized by division
with the corresponding antigen cut-off. These normalized values
were used to assess the ratio between the antigens. The
logarithm to base 10 of normalized optical densities was used for
comparative graphical representation. The values of sensitivity
(Se), specificity (Sp), positive predictive value (PPV), and
negative predictive value (NPV) were calculated for each antigen
ratio. The ROC curves, Unpaired t test with Welch’s correction,
One-way ANOVA, Mann-Whitney, and Kruskal-Wallis tests
were performed using GraphPad Prism 5 software (GraphPad
Software, USA).
RESULTS
Evaluation of Seroreactivity at M1 Time
Point
ROC curves were determined for all antigens and cut-off
values inferred (Supplementary Table 1). One month after
FIGURE 1 | Seroreactivity at M1 for non-vaccinated (NV) and vaccinated (V)
dogs to the different antigens. Graphical representation of the median
serological response to SPLA, rK39, rK28, LicTXNPx, and rKDDR. Results are
expressed as the logarithm of the optical density values normalized by the
cut-off for each antigen. Each dot represents the average of at least two
independent experiments performed in triplicate. Statistical analysis was done
by Unpaired t test with Welch’s correction. One level of significance is
represented: “extremely significant” (***0.0001 ≤ P < 0.001).
primo-vaccination, the reactivity to SPLA was significantly
increased (P = 0.0007) in vaccinated dogs (V) when
comparing to non-vaccinated (NV) (Figure 1). In fact,
from the 20 vaccinated animals, 10 presented serology
above the defined cut-off for SPLA at M1 time point. The
reactivity to rK39, rK28, LicTXNPx, and rKDDR antigens
for V and NV groups in this time point was not significantly
different (P < 0.05).
Evaluation of Seroreactivity at M25 Time
Point
The V-, V+, C-, and C+ reactivity to the 5 antigens tested,
was analyzed at the M25 time point (Figure 2). In non-
vaccinated dogs, all tested antigens were significantly more
recognized by the infected animals when compared to the non-
infected group (Figure 2). When considering just vaccinated
animals, only rK39 was able to significantly discriminate
infected from non-infected animals (P = 0.0225). The antigen
recognition in V- and C- was not significantly different for
the recombinant antigens. The same was not true for SPLA
that was significantly more recognized in V- (P = 0.0015)
(Figure 2A). In fact, 25months after immunization all vaccinated
animals were seropositive to SPLA. Nine V- animals were
also seropositive to LicTXNPx being the second antigen with
most seropositive animals in this group (Figure 2D). For
the other antigens tested, the V- group contained at most
one seropositive animal. Concerning the infected animals,
the serological response to the different antigens in the V+
and C+ groups was not significantly different for all the
antigens tested. Still, with the exception of SPLA, the percentage
of seropositive animals was higher in C+ when compared
to V+.
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FIGURE 2 | Seroreactivities at M25 in C-, C+, V-, and V+ groups against SPLA, rK39, rK28, LicTXNPX, and rKDDR antigens. Graphical representation of the median
serological response to SPLA (A), rK39 (B), rK28 (C), LicTXNPx (D), and rKDDR (E). Results are expressed as the logarithm of the optical density values normalized
by the cut-off for each antigen. Each dot represents represent the average of at least two independent experiments performed in triplicate. Statistical analysis was
done by one-way ANOVA and Kruskal-Wallis tests. Three levels of statistical significance are represented: “significant” (*0.01 ≤ P < 0.05), and “very significant”
(**0.001 ≤ P < 0.01).
Seropositivity Ratios for Detection of
Vaccinated Non-infected Dogs
To understand if the pattern of seropositivity to SPLA and
seronegativity to the recombinant antigens had some predictive
characteristic value (Table 1), the ratios between the normalized
responses to each antigen (rK39, rK28, LicTXNPx, and rKDDR)
and SPLA were calculated for V-, V+, C- and C+ groups
(rK39/SPLA, rK28/SPLA, LicTXNPx/SPLA, rKDDR/SPLA) and
ROC curves were calculated (Supplementary Table 2). A cut-
off value for each ratio was inferred by the respective ROC
curve and used to normalize the data, which was then
logarithmized (Figure 3). As observed by the ROC curves
and by the graphical representation of the ratios rK39/SPLA,
rK28/SPLA, LicTXNPx/SPLA, and rKDDR/SPLA, the ratio
that performed better was rK39/SPLA. The ratio rK39/SPLA
represented the best compromise between Se (92.3%) and
Sp (95.4%), and consequently, the best compromise between
positive predictive value (92.8%) and negative predictive value
(95.6%) (Supplementary Table 3).
DISCUSSION
In the reported study, seropositivity to 5 different antigens
was evaluated in a cohort of vaccinated/non-vaccinated animals
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with CaniLeish that were followed up at 1 and 25 months
after Primo-vaccination. At a serological level, after 1 month of
vaccination, the group of vaccinated animals (V) was significantly
TABLE 1 | Comparison of seropositivity observed for SPLA with seronegativity
observed for the antigens rK39, rK28, LicTXNPx, rKDDR, LAM, and RPM at M25
time point.
SPLA/rK39 SPLA/rK28 SPLA/LicTXNPx SPLA/rKDDR
V- 92.3(12/13) 92.3(12/13) 38.5(5/13) 100(13/13)
V+ 42.8(3/7) 42.8(3/7) 28.6(2/7) 42.8(3/7)
C- 33.3(2/6) 16.7(1/6) 0.0(0/6) 33.3(2/6)
C+ 22.2(2/9) 0.0(0/9) 11.1(1/9) 22.2(2/9)
Total* 31.8(7/22) 18.2(4/22) 13.6(3/22) 31.8(7/22)
*All non V- dogs.
more reactive to SPLA suggesting an early seroconversion
that was maintained. In fact, the response of the V- to
SPLA was indistinguishable from the V+ and C+. This
reactivity to SPLA resulting from vaccination might translate
into cross-reactivity to other tests like IFAT or DAT that
rely on the identification of total parasite antigens. In fact,
at M25 time point, all vaccinated animals tested positive
to IFAT (Supplementary Table 3). This observation was also
reported by Moreno et al. (24) and Oliva et al. (8). This
is not surprising as the secreted material from the parasite
contains several surface and intracellular antigens that can
be recognized during a normal infection (14, 25). On the
contrary, the recombinant antigens tested were not recognized
significantly by the non-infected vaccinated group (Figure 2).
The antigen LicTXPx was an exception, presenting a distinct
FIGURE 3 | Seroreactivities at M25 in C-, C+, V-, and V+ groups for the antigen/SPLA ratios. Graphical representation of the response to rK39/SPLA (A), rK28/SPLA
(B), LicTXNPx/SPLA (C), and rKDDR/SPLA (D). Results are expressed as the logarithm of the optical density values normalized by the cut-off for each antigen. Each
dot represents represent the average of at least two independent experiments performed in triplicate. Statistical analysis was done by one-way ANOVA and
Kruskal-Wallis tests. Three levels of statistical significance are represented: “significant” (*0.01 ≤ P < 0.05), “very significant” (**0.001 ≤ P < 0.01), and “extremely
significant” (***0.0001 ≤ P < 0.001).
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behavior with eight seropositive from 13 infected dogs. A possible
explanation for this unique behavior might be the possibility of
undetected asymptomatic infections. This antigen is a potential
serological marker in detecting asymptomatic infection and in
early seroconversion (18, 26). Therefore, we cannot rule out
that the increase in reactivity to this antigen in V- group might
be due to a low intensity (undetected by PCR) asymptomatic
infection. Considering the serology results obtained it is clear
that CaniLeish vaccination abrogates the usefulness of SPLA and
other techniques that rely on the detection of parasites like, IFAT,
DAT. Recombinant antigens were not able to detect vaccinated
healthy animals not enabling the detection of vaccinated animals
in field surveys.
Considering that the vaccine-associated reactivity to SPLA
was the only measure of exposure to the vaccine, seropositivity
to SPLA, and seronegativity to any given antigen would be
a serological profile characteristic of vaccinated non-infected
animals as is depicted in Table 1. In V- group, with the exception
for LicTXNPx, the pattern of SPLA seropositive and seronegative
to recombinant proteins—rK39, rK28, rKDDR, LicTXNPx– was
observed in at least 11 of the 13 animals (84.6%), and in all
13 dogs for SPLA+/rKDDR- (100%). Nonetheless, this profile
although observed in the V- group was also present in a
lesser extent (13.6–31.8%, dependent on the antigen), in the
C- group. Considering this scenario, a different approach was
tested. We had already reported that the relationship between the
seropositivity to rK39 and SPLA presented a pattern that could be
predictive of disease associated seropositivity (27), this was once
again confirmed in the context of vaccination (Figure 3). In fact,
by performing the ratios between the four antigens and SPLA
(rK39/SPLA, rK28/SPLA, LicTXNPx/SPLA, rKDDR/SPLA) and
respective ROC curves, we could for the first time distinguish the
V- (vaccinated healthy animals) from the other groups studied
(V+, C-, and C+). In fact, the rK39/SPLA ratio (with 92.3% of Se
and 95.4% of Sp) performed the best in distinguish V- animals,
which is more informative than the cumulative seropositivity to
the individual antigens.
In conclusion, we reported the serological response to
different antigens in the context of CaniLeish vaccination
confirming that SPLA is recognized by vaccinated animals
limiting the use of IFAT, DAT and total antigen ELISA. We
also confirm that the vaccine does not induce significant
serological responses to rK39, rK28, LicTXNPx, and rKDDR.We
also presented a new approach that enabled the identification
of seropositive vaccinated healthy animals from vaccinated
parasitized animals, non-vaccinated parasitized animals and
non-vaccinated healthy animals, using the relation between
the seroreactivities of two different antigens (SPLA and
rK39) as a form of DIVA (Differentiating Infected from
Vaccinated Animals) for CaniLeish. Ultimately, the evaluation
of specific serological profiles associated with quantitative
serology might enable the discrimination of not only vaccinated
animals, as was proposed, but also contribute to finding
specific serologic imprints associated do symptomatic and
asymptomatic disease.
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